Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Status:
Recruiting
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized
pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when
administered intratumorally in microdose quantities via the CIVO device in patients with
surface accessible solid tumors for which there is a scheduled surgical intervention. CIVO
stands for Comparative In Vivo Oncology. Multiple substudies will include specified
investigational agents and combinations to be evaluated.